AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02697253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours.
Trial: NCT02040480
Drug: GSK2110183 IR Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
Trial: NCT00987974
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg/day for 3 days.
Trial: NCT00987974
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 3 days.
Trial: NCT00987974
Drug: rosuvastatin 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/day for 7 days
Trial: NCT00987974
Drug: placebo 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 7 days
Trial: NCT04139395
Drug: 68Ga-Citrate PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
Trial: NCT01297062
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo (matching volume of placebo)
Trial: NCT01694537
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Trial: NCT01694537
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is made with same size and shape with study drug.
Trial: NCT00003135
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003135
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02967302
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT01714128
Drug: Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES-PET/CT imaging
Trial: NCT03119857
Drug: Antiandrogen
RxNorm normalized name: Antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01604330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
Trial: NCT03371420
Drug: PU-AD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00755482
Drug: Aquamin F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755482
Drug: Placebo (maltodextran)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03491553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
Trial: NCT03491553
Drug: Hepatitis B virus (HBV) OAV Therapy
RxNorm normalized name: hepatitis B virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Trial: NCT00157937
Drug: Comparator: theophylline ER/Duration of Treatment: 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01025817
Drug: mycophenolate mofetil and tacrolimus
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
Trial: NCT02959996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection in the Pfannenstiel incision
Trial: NCT00039195
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00039195
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02754830
Drug: LY3303560 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02754830
Drug: Saline Solution - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02754830
Drug: LY3303560 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01996748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two administrations daily for 7 days
Trial: NCT02268006
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03000387
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patches of 21 mg, 14 mg and 7 mg
Trial: NCT02242825
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00679731
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5.0 to 25 mg weekly
Trial: NCT02205606
Drug: HGP0816 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT02205606
Drug: HGP0816 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT02205606
Drug: HGP0816 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT02205606
Drug: HCP1306 5/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT02205606
Drug: HCP1306 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT02205606
Drug: HCP1306 20/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT00059722
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00059722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00059722
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03972488
Drug: 2.5% Lys-Arg sterile amino acid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
Trial: NCT00121992
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00121992
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01597427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of placebo solution.
Trial: NCT00414960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po QD for 6 months
Trial: NCT01600768
Drug: Beta-Lactams
RxNorm normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion time: 30 mins or 1 hr
Trial: NCT01600768
Drug: Beta-Lactams
RxNorm normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion time 4 hrs
Trial: NCT01763281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004038
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00511524
Drug: [carbonyl-^11C]GW842166
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
Trial: NCT02713191
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
Trial: NCT03733873
Drug: Suoquan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take Suoquan mixture for 3 months
Trial: NCT04123717
Drug: Intravenous Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
Trial: NCT03089216
Drug: 8% arginine and calcium carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using during all the treatment.
Trial: NCT00259220
Drug: erythomycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erythomycin
Trial: NCT00706667
Drug: Ferinject ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
Trial: NCT00622869
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
Trial: NCT03177980
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
Trial: NCT02487225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
Trial: NCT03177980
Drug: Fentanyl and clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
Trial: NCT01918995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT02213302
Drug: placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04425564
Drug: metronomic XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03976115
Drug: DDO-3055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03976115
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01317615
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
Trial: NCT01287533
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monthly dosage of ibandronate 150mg
Trial: NCT01287533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monthly dosage of placebo
Trial: NCT00006248
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00703755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03996434
Drug: Antagonist
RxNorm normalized name: Purine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate 0.25 mg
Trial: NCT02456857
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01983774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT04564872
Drug: HSK7653 10 mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Trial: NCT04564872
Drug: HSK7653 25 mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
Trial: NCT01445938
Drug: SAR97276A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular
Trial: NCT04480697
Drug: HPG1860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo
Trial: NCT00005834
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
Trial: NCT03000374
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
Trial: NCT03000374
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Trial: NCT00625898
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Trial: NCT02517320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03121833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500ml 0.9% sodium chloride
Trial: NCT03121833
Drug: AIM regimen / GT regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)
Trial: NCT02101840
Drug: OxyNEO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
Trial: NCT02101840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
Trial: NCT00228150
Drug: SR57667B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02920515
Drug: Triptorlin or Leuprorelin
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone agonists (GnRHa)
Trial: NCT02920515
Drug: Zhibo dihuang pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine
Trial: NCT02920515
Drug: Dabu ying pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine
Trial: NCT02375958
Drug: PCA062
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00484536
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, once daily
Trial: NCT00789958
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT
Trial: NCT00074724
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
Trial: NCT02622724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for investigational drug
Trial: NCT00296725
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
Trial: NCT01925638
Drug: BAY86-9766
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02230878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo from Day 1 up to Day 10.
Trial: NCT02746185
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
Trial: NCT01521377
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single inhalation from GSK573719 500mcg DPI once daily
Trial: NCT01521377
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Inhalation from matching Placebo DPI once daily
Trial: NCT01604057
Drug: ZT-034 Mid Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray
Trial: NCT01604057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray
Trial: NCT01592032
Drug: Tigecycline antimicrobial-lock solution
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Trial: NCT01000727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered
Trial: NCT04615702
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters.
Trial: NCT00074282
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03448978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous cyclophosphamide
Trial: NCT00783744
Drug: Insulin monotherapy with premixed insulin NPH 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
Trial: NCT00920426
Drug: GSK1265744 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 30 mg
Trial: NCT00920426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK1265744
Trial: NCT00920426
Drug: GSK1265744 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 5mg
Trial: NCT01292603
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1-3 or Days 1-5 of cycles 1-6
Trial: NCT01759589
Drug: Remifentanil and propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
Trial: NCT03303092
Drug: TEV-48125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.
Trial: NCT03303092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Trial: NCT01170117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group will receive placebo pill
Trial: NCT01820728
Drug: Gonal-F®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02150473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo the same amount as adalimumab
Trial: NCT02152670
Drug: Alpha Methyl Para Tyrosine (AMPT)
RxNorm normalized name: α-methyl-para-tyrosine
DrugBank: Metyrosine (DB00765)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00489606
Drug: SK3530
FDA approved: no
EMA approved: no
PMDA approved: no